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February 2016 Abstracts S3Deep sequencing of circulating tumor
DNA for personalized lung cancer
detection and radiotherapy response
monitoringMaximilian Diehn Stanford University,
Stanford, CACirculating tumor DNA (ctDNA) represents a promising
biomarker for sensitive, speciﬁc, and dynamic detection
of disease burden in cancer patients. Mutations in
tumor-derived DNA represent ideal potential biomarkers
since they are highly speciﬁc to tumor cells and involved
in disease pathogenesis. However, even in advanced
cancer patients, concentrations of ctDNA are often very
low and therefore difﬁcult to detect. We have developed
a novel, ultra-sensitive and speciﬁc method for detection
of circulating tumor DNA called Cancer Personalized
Proﬁling by Deep Sequencing (CAPP-Seq). This method
was developed speciﬁcally for detection of ctDNA in non-
small cell lung cancer patients, although it is broadly
applicable to other cancer types. In this presentation I
will describe recent improvements to CAPP-Seq that
further improve the sensitivity of the assay, with a focus
on applications of ctDNA analysis in lung cancer patients
treated with radiotherapy.
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SCLC accounts for w15% of all lung cancer cases and
w220,000 deaths annually worldwide. Although
response rates to ﬁrst line platinum-based chemo-
therapy are high (w80%), progression free survival in
most patients is short (3-12 months) due to the
development of chemotherapy resistance and pro-
gressive disease. In addition, approximately 20% of
SCLC patients are classiﬁed as chemorefractory with
progressive disease within 3 months of their initial
treatment. The lack of durable chemotherapy re-
sponses contributes to the poor prognosis in SCLC;
with a 5 year survival rate of w5% (5,6). Platinum
based chemotherapy regimens have remained the same
as standard of care for SCLV for the past 30 years.
Targeted therapies have yet to make impact on patient
outcomes, although several ongoing clinical trials ofsmall molecular and immunotherapies begin to show
promise.
The majority of SCLC patients present with metastatic
disease and < 5% patients are suitable for resection
with curative intent. Biopsies of SCLC are generally
challenging, often providing a low quantity and quality of
specimen for research purposes: specimens are usually
necrotic and exhibit crush artefact. Serial biopsy in SCLC
is rare. Understanding the biology of drug resistant,
advanced and progressive disease is hampered by
limited clinical specimens to study. In SCLC, CTCs
detected by the EpCAM dependent CellSearch platform
are prevalent, CTC number is prognostic for overall and
progression free survival, the dynamic range is sufﬁcient
to use CTC number as a pharmacodynamic biomarker
and predictive CTC based biomarkers are feasible.
Marker independent CTC enrichment platforms reveal
the presence of EpCam negative SCLC CTCs. To address
the paucity of SCLC biopsies for research, we recently
developed Circulating Tumour Cell patient Derived
eXplant models in immune-compromised mice (CDX,
Hodgkinson et al, Nature Medicine, 2015).
I will describe our SCLC CDX panel derived from
chemosensitive and chemorefractory patients at baseline
and CDX matched pairs at baseline and progression. The
CDX models tested to date mirror patient responses to
standard of care chemotherapy. These models are being
exploited to search for new drugable targets, to test
targeted treatments and to interrogate treatment resis-
tance mechanisms. As few as 10 SCLC CDX cells can
recapitulate the CDX tumour suggesting a high frequency
of SCLC ‘stem-like’ cells. We also discovered that a subset
of SCLC CTCs exhibit vasculogenic mimicry, a ‘stem-like’
angiogenic switch whereby tumour cells form their own
blood vessel walls. The clinical relevance of this biology
is under investigation using CDX and xenograft models.
We hypothesize that VM facilitates dissemination, but
may also enhance drug delivery and alleviate hypoxia.
In summary, our SCLC CDX models of metastatic lung
cancer offer new avenues to study biology, mechanisms
of tumor cell dissemination.Immunotherapy in small cell lung
cancerAnna Farago Massachusetts General Hospital
Cancer Center, Boston, MASmall cell lung cancer (SCLC) is a high-grade neuroen-
docrine malignancy that accounts for approximately
15% of all lung cancers in the United States. Patients
with metastatic disease have a median survival of less
than one year, and despite a large number of early phase
